205 related articles for article (PubMed ID: 17137731)
21. Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement.
Rives S; Alcorta I; Toll T; Tuset E; Estella J; Cross NC
J Pediatr Hematol Oncol; 2005 Dec; 27(12):663-5. PubMed ID: 16344672
[TBL] [Abstract][Full Text] [Related]
22. F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance.
Gorantla SP; Zirlik K; Reiter A; Yu C; Illert AL; Von Bubnoff N; Duyster J
Leukemia; 2015 Aug; 29(8):1763-70. PubMed ID: 25761934
[TBL] [Abstract][Full Text] [Related]
23. Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.
Capovilla M; Cayuela JM; Bilhou-Nabera C; Gardin C; Letestu R; Baran-Marzak F; Fenaux P; Martin A
Eur J Haematol; 2008 Jan; 80(1):81-6. PubMed ID: 18028420
[TBL] [Abstract][Full Text] [Related]
24. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ
J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119
[TBL] [Abstract][Full Text] [Related]
25. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
Miyazawa K; Kakazu N; Ohyashiki K
Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
[TBL] [Abstract][Full Text] [Related]
26. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.
Cools J; Stover EH; Wlodarska I; Marynen P; Gilliland DG
Curr Opin Hematol; 2004 Jan; 11(1):51-7. PubMed ID: 14676627
[TBL] [Abstract][Full Text] [Related]
27. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
Lierman E; Michaux L; Beullens E; Pierre P; Marynen P; Cools J; Vandenberghe P
Leukemia; 2009 May; 23(5):845-51. PubMed ID: 19212337
[TBL] [Abstract][Full Text] [Related]
28. Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report.
Yamamoto M; Ikuta K; Toki Y; Hatayama M; Shindo M; Torimoto Y; Okumura T
Medicine (Baltimore); 2017 Sep; 96(36):e8001. PubMed ID: 28885361
[TBL] [Abstract][Full Text] [Related]
29. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
Li B; Zhang GS; Dai CW; Pei MF
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
[TBL] [Abstract][Full Text] [Related]
30. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
[TBL] [Abstract][Full Text] [Related]
31. [New insights into hypereosinophilic syndromes].
Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
[TBL] [Abstract][Full Text] [Related]
32. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
Ng HJ; Tan DC; Yiu RC; How GF
Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
[TBL] [Abstract][Full Text] [Related]
33. Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity.
Chung KF; Hew M; Score J; Jones AV; Reiter A; Cross NC; Bain BJ
Eur Respir J; 2006 Jan; 27(1):230-2. PubMed ID: 16387954
[TBL] [Abstract][Full Text] [Related]
34. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
35. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
Klion AD; Robyn J; Maric I; Fu W; Schmid L; Lemery S; Noel P; Law MA; Hartsell M; Talar-Williams C; Fay MP; Dunbar CE; Nutman TB
Blood; 2007 Nov; 110(10):3552-6. PubMed ID: 17709602
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature.
Müller AM; Martens UM; Hofmann SC; Bruckner-Tuderman L; Mertelsmann R; Lübbert M
Ann Hematol; 2006 Jan; 85(1):1-16. PubMed ID: 16136348
[TBL] [Abstract][Full Text] [Related]
37. Generalized Eruptive Histiocytosis Associated With FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia.
Ziegler B; Peitsch WK; Reiter A; Marx A; Goerdt S; Géraud C
JAMA Dermatol; 2015 Jul; 151(7):766-9. PubMed ID: 25923837
[TBL] [Abstract][Full Text] [Related]
38. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
[No Abstract] [Full Text] [Related]
39. FIP1L1/PDGFR alpha-associated systemic mastocytosis.
Yamada Y; Cancelas JA
Int Arch Allergy Immunol; 2010; 152 Suppl 1(Suppl 1):101-5. PubMed ID: 20523072
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].
Menif S; Ben Romdhane N; Hafsia R
Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
